Pfizer Inc faces a new challenge as Enanta Pharmaceuticals sues over a patent infringement concerning Paxlovid in the EU.

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a ...

AI is making an impact in the early stages of drug discovery. It can scan huge chemical and biological datasets, predict how ...

In the fourth part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, discusses how healthcare ...

The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Since COVID, there've been growing initiatives in Africa to start producing vaccines and medicines locally, thus gaining greater independence from global supply chains. But are these schemes ...

A 15% import tariff on pharmaceutical goods from the European Union to the US is going to have a lesser impact on the pharmaceutical industry than Wall Street feared. Big pharmaceutical stocks like ...

Pfizer stock currently trades at very low volatility. That could mean it’s ripe for a breakout trade, like a long strangle.

Pfizer faces challenges from pricing pressures, a 2026 patent cliff, and weak R&D momentum. Click here to find out why I rate PFE stock a Sell.

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green ...